Vanta Bioscience Share Price Today | Stock Price & Vanta Bioscience Share Screener
Track the current Vanta Bioscience share price and stock price live with TickJournal's free stock screener. Check VANTABIO price range for the annual price range and momentum. Use the Vanta Bioscience stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Vanta Bioscience opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹1 and net income of ₹-1, with EBITDA of ₹-1, an operating margin of -206.0% and a profit margin of -100.0%.
Vanta Bioscience Share Price Chart
Track the current stock price of Vanta Bioscience with an interactive chart. Analyse VANTABIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Vanta Bioscience stock quote in one place.
Vanta Bioscience Company Profile - Fundamental Screener
Screen Vanta Bioscience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VANTABIO shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Healthcare Technology industry, and it trades under ISIN INE695X01011.
Company Details
Classification
Identifiers and Leadership
Vanta Bioscience Balance Sheet Screener
Screen VANTABIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹66, down from ₹86 in 2025.
Latest statistics put total assets at ₹66 and shareholder funds at ₹21, with a leverage ratio of 5.11.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
Assets |
||||||||
| Total Assets | 66 | 86 | 85 | 85 | 81 | 70 | 49 | 39 |
| Current Assets | 14 | 15 | 17 | 15 | 15 | 20 | 20 | 17 |
| Fixed Assets | 48 | 56 | 54 | 57 | 36 | 29 | 21 | 18 |
Liabilities |
||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 33 | 56 | 50 | 48 | 34 | 29 | 14 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||
| Total Equity | 21 | 4 | 13 | 19 | 29 | 26 | 25 | 23 |
| Share Capital | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 14 | 4 | 9 | 11 | 18 | 18 | 17 | 16 |
Vanta Bioscience Income Statement Screener - Profit & Revenue Analysis
Screen Vanta Bioscience income statement and profit fundamentals. Analyze VANTABIO quarterly results. Vanta Bioscience reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2023-Mar, revenue was ₹1 and net profit was ₹-1, at an operating margin of -206%.
In that period expenses were ₹2, interest cost ₹1 and tax ₹0. The next period listed, 2022-Dec, shows revenue of ₹3 and net profit of ₹-3.
| Item | 2023-Mar | 2022-Dec | 2022-Mar | 2021-Dec |
|---|---|---|---|---|
Revenue and Expenses | ||||
| Revenue | 1 | 3 | 5 | 0 |
| Expenses | 2 | 3 | 2 | 0 |
Operating Costs and Margins | ||||
| EBITDA | -1 | -1 | 2 | 0 |
| Operating Profit % | -206.00% | -20.00% | 46.00% | 0.00% |
| Depreciation | 0 | 1 | 1 | 0 |
| Interest | 1 | 3 | 1 | 0 |
Profit and Earnings | ||||
| Profit Before Tax | -2 | -4 | 1 | 0 |
| Tax | 0 | -2 | 0 | 0 |
| Net Profit | -1 | -3 | 0 | 0 |
| EPS | 0.00 | -4.06 | 0.11 | 0.00 |
Vanta Bioscience Cash Flow Screener - Liquidity Fundamentals
Screen VANTABIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹2.
Over the same period, investing activities used ₹7 and financing activities provided ₹9.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||
| Operating Activities | -2 | 3 | -1 | 5 | 7 | 2 | -1 |
| Investing Activities | -7 | -3 | -6 | -17 | -22 | -8 | -6 |
Financing and Net Cash | |||||||
| Financing Activities | 9 | 1 | 6 | 10 | 18 | 2 | 10 |
| Net Cash Flow | 0 | 0 | 0 | -2 | 3 | -3 | 3 |
Vanta Bioscience Shareholding Pattern Screener
See Vanta Bioscience shareholding pattern with promoter, FII, and DII holdings. Check Vanta Bioscience promoter holding and ownership changes for VANTABIO on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 72.81%, foreign institutions 0.00%, domestic institutions 0.00% and the public 24.51%, spread across 426 shareholders.
The shareholder count was 426 in 2026-Mar, compared with 408 in 2025-Mar.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Sept | 2023-Mar | 2023-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 72.81% | 69.36% | 72.81% | 72.81% | 69.36% | 69.36% | 69.36% | 69.36% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 24.51% | 26.35% | 23.39% | 23.66% | 25.97% | 26.55% | 26.77% | 26.77% |
| Other Holding | 2.68% | 4.29% | 3.81% | 3.53% | 4.67% | 4.09% | 3.87% | 3.87% |
| Shareholder Count | 426 | 408 | 408 | 419 | 418 | 424 | 394 | 388 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Vanta Bioscience. Vanta Bioscience dividend yield can be compared with peers and other stocks in the market.
Vanta Bioscience Stock Index Membership - Nifty & Sensex
See which indices include Vanta Bioscience stock. Check VANTABIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Vanta Bioscience Market Events Screener - Corporate Actions
Get Vanta Bioscience corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Vanta Bioscience stock events that may affect VANTABIO share price, along with derivatives, futures and options activity and sector gainers.
8 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Quarterly Result Announcement dated May 30, 2026 and Quarterly Result Announcement dated November 14, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | 4.53% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -4.99% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -5.00% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | 4.98% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 18.62% |
| 2025-01-04 | 2025-01-04 | Extraordinary General Meeting | NA | -2.97% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -9.75% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 9.19% |
Vanta Bioscience Competitors Screener - Peer Stocks Comparison
Screen VANTABIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 9 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Syngene International | 14,770 | 68.69 | 3,809 | 2.56% | 317 | 39.42 |
| Indegene | 14,581 | 36.84 | 3,583 | 21.58% | 401 | 65.95 |
| Suven Life Sciences | 9,155 | -25.81 | 21 | 19.32% | -276 | 38.29 |
| Vimta Labs | 2,644 | 35.09 | 322 | 0.22% | 41 | 37.53 |
| Bilcare | 237 | -37.75 | 764 | -5.33% | -17 | 55.07 |
| TAKE | 207 | 16.89 | 61 | 497.06% | 4 | 35.50 |
| Jeevan Scientific Technology | 163 | 30.25 | 62 | 29.56% | 2 | 46.75 |
| Adeshwar Meditex | 24 | 33.09 | 56 | -33.21% | 1 | 52.35 |
| Vanta Bioscience | 15 | 136.87 | 2 | -13.33% | 0 | 44.45 |
Vanta Bioscience Company Announcements - News & Reports Screener
Screen VANTABIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated October 1, 2026 and September 5, 2026.
| Date | Update | Actions |
|---|---|---|
| Closure of Trading Window | - | |
| 2026-10-01 | Reg. 34 (1) Annual Report. | - |
| 2026-09-05 | Board Meeting Outcome for Outcome Of Board Meeting Held On 05.09.2026 - 10Th Annual General Meeting (AGM) To Be Held On 30.09.2026 | - |
| 2026-05-30 | Audited Standalone And Consolidated Financial Results For The Half Year And Financial Year Ended March 31 2026 | - |
| 2026-05-30 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 30.05.2026 | - |
| 2026-05-26 | Board Meeting Intimation for Approval Of Standalone And Consolidated Audited Financial Results For The Half Year And Financial Year Ended March 31 2026 - Board Meeting To Be Held On May 30 2026 | - |
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-24 | Closure of Trading Window | - |
| 2026-03-11 | Clarification On Movement In Price | - |
| 2026-02-25 | Clarification sought from Vanta Bioscience Ltd | - |
| 2026-01-30 | Board Meeting Outcome for Outcome Of The Board Meeting - Appointment Of Company Secretary And Compliance Officer | - |
| 2025-11-14 | Financial Results For The Half Year Ended September 30 2025 | - |
| 2025-11-14 | Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14 2025 | - |
| 2025-11-08 | Board Meeting Intimation for Board Meeting To Be Held On 14.11.2025 | - |
| 2025-11-01 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2025-11-01 | Reg. 34 (1) Annual Report. | - |
| 2025-10-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2025-09-30 | Closure of Trading Window | - |
| 2025-09-06 | Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2025 | - |
Frequently Asked Questions
How is the company valued right now?
The P/B ratio is 0.69. Market capitalisation stands at ₹15.33 Cr. The company operates in the Healthcare sector, in the Healthcare Technology industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 6, 2026. This page covers 8 balance sheet periods, 4 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.